Canada markets close in 3 hours 41 minutes

Roche Holding AG (RHHBF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
365.550.00 (0.00%)
As of 03:13PM EDT. Market open.

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • s
    simon
    Does Roche try and get back into the kidney market with buying Aveo
  • B
    Bux
    FDA APPROVED - Roche test kits
  • c
    choo
    Ark Invest has begun purchasing RHHBY in their ARKG fund. I believe it's due to Roche's heavy investment in individualized cancer immunotherapy. Roche plans to deliver individualized blood testing on individuals with cancer to determine their cancer's genetic profile. The cancers genetic profile will then be used to individualize cancer therapies to the patients. Also, according to Morningstar, Roche is a wide moat stock that is very undervalued (five stars). Long!!!!!
  • B
    Bill
    You should buy ACIU (AC IMMUNE) if you want Alzheimer drug exposure, with among the best risk/rewards I have ever seen. ACIU has the broadest portfolio of development stage Azlheimer's drugs with top partners such as Biogen, Eli Lilly, Roche and AbbVie. ACIU has the potential to earn $15 bil in revenues from royalties and payments The market cap of the company is only $400 mil, with $316 mil of net cash, resulting of an enterprise value of only $87 mil. If even one of ACIU's drugs go into commercial production, the stock could go up 10x or more, with limited near-term downside due to the company's strong cash position. ACIU has several drugs in its development pipeline in both stage 1 and stage 2 development, so investors have many shots at goal. There is a huge catalyst coming up on Nov 7th when the company will host a conference on the progress of their drug candidates. Investors have not started paying attention yet, but I think that will happen shortly. I have attached a recent positive recommendation on the stock from Value Investors, which is among the most reputable investors club. https://www.valueinvestorsclub.com/idea/AC_IMMUNE_SA/9888338509
  • A
    AJ
    Roche (OTCQX:RHHBY) unit, Genentech announces that tiragolumab, a novel cancer immunotherapy designed to bind to TIGIT, has been granted Breakthrough Therapy Designation (BTD) by the FDA, in combination with Tecentriq (atezolizumab) for the first-line treatment of people with metastatic non-small cell lung cancer (NSCLC).
    Breakthrough Therapy status provides for more intensive guidance from the FDA on development, the involvement of more senior agency personnel and a rolling review of the marketing application.
  • H
    H
    Roche Holding AG said on Monday it has received the U.S. Food and Drug Administr...
    Roche Holding AG said on Monday it has received the U.S. Food and Drug Administr...
    www.reuters.com
  • T
    TOM
    To clarify further on the two analyzers from Roche, the newest one can analyze over 4000 cases in 24 hours and have the results within four hours. There are quite a large number of analyzers in the United States and in the rest of the world. Now a patient can get their results within a few hours, not days or weeks which is important to the growth  statistics to determine what’s happening in our country in any locale.
  • A
    Andy
    This company would have to cure cancer for it to move up significantly. Good news almost every week and ARK buying thousands of shares and it goes down or barely moves up.
  • S
    Scott
    Roche approaching another new high... Slowly but surely creating wealth for shareholders. Best in class biotech and diagnostics play IMO.
  • D
    Donald
    We hear so much about the test kits and that is fine. But, the great news that we don't hear much about is Roche's drug Actemra which blocks the function of interleukin-6 causing inflammation in the lungs for those infected with the Corona virus. It was used with success to keep people off ventilators in China who did well. All 21 people in their trial did well. It was also used with success in Italy. The results were impressive so says Regeneron who has a similar drug called Kevzara. They have started a trial with their drug which could be ready in abundance by summer. So, Regeneron stock is soaring . Roche stock should be soaring as well.
  • b
    bpowers
    Okay, now that it's approved the US Government should put it to good use. The Red Cross is clearly in need of blood during this pandemic and the Roche test requires a blood draw. The government should provide these tests to the Red Cross so that they can encourage Americans to come in, give blood and get a free anti body test for their efforts. I'm sure they are many people who don't want to go into a standard lab right now. I suspect that there are just as many who don't want to give blood. But if one can give blood in a Covid free environment and get antibody test in the process then it sounds like a win win for everyone.
  • A
    Andy
    Nothing seems to move this stock. News of an FDA approval and it goes down.
  • D
    Dee
    This is a gold mine. They are supplying test kits to the US, WHO, and other countries. Apply the law of supply and demand, test kit price goes up when demand is increase. I can't imagine the revenue they are going make by selling this kit.

    https://www.roche.com/dam/jcr:7a1981f0-3b90-434e-b026-3c1a41194e09/en/200304_Update_Statement_roche.pdf
  • S
    Scott
    Roche expected to acquire ONCE (Spark Therapeutics) for $5B, which is a significant premium over current $2B valuation. Curious was Roche holders think about the potential deal.
  • B
    Bear
    4000$ per system * 400k per week Shipment
    Let’s say 4 week they will ship so 6.4B 40$ per test let’s see testing 1M people in usa next quarter so 40m
    Total usa revenue let’s say 6.5B
    Roche sent test system to other countries let’s say 4 more countries
    So total 22B revenue increased this quarter
  • M
    Mark
    There is a rumor coming from one of the biggest consultings in the world which states that "The Pharmatheutical Swiss company Roche is about to announce the launching of a takeover bid over the little Spanish Biotecnological company Pharmamar S.A.The takeover bid amounts to 159#$%$ per share, with a total operation of 2950 millions euros and it would be launched within the second half of september.The Spanish company actually has three marine based drugs in the market to treat oncologic diseases as well as a large portofolio composed by 1500 patents and 180.000 molecules that could supply all Roche companies and affialiates to begin investigations for all kind of diseases.Pharmamar also has a promising drug under study "Plitidepsin" which as the company states it could be the most powerful antiviral ever discovered, which has attract several Pharmatheutics like Roche.Since the acquisition of Genentech, Roche's politics have been to make bigger, buying small and medium Biotecnologic companies such as Seragon, InterMune, Ignyta, Genia, Jecure, Illumina, Spar Therapeutics, Trophos, Santarias Pharma or Foundation Medecine.According to these sources, several Founds that have invested in the Spanish Comoany during the last years, would accept the takeover bid to sell their shares and collect capital gains due to a possible upcoming potential worldwide crisis in other sectors of their investments.These Founds would have a minimum of 16% of participation, the 22% of Steakholders belongs to the company management group and then there would be a free float of around 60%.Big Found as Vanguards, Blackrock, Norges Bank, Dimensional Fund, Findel, Schroder Investment or Northern Trust are already positioned in the company Pharmamar S.A
  • A
    Andy
    I like this investment, you can see that is not a rocket and optical illusion like other CV Test diagnostic startups.
  • M
    Mike
    453k shares bought by ark. Moon tomorrow
  • O
    Owen
    Roche has partnered with Regeneron to produce it's antibody cocktail and deliver the doses on a massive scale per President Trump's request:

    Dr. George Yancopoulos, Regeneron's president and chief scientific officer, told CNN's Julia Chatterley in an interview Monday that the company is hoping it can get more doses of REGN-COV2 to patients within the next few months thanks to a partnership with Big Pharma giant Roche.

    "We are on track to deliver 300,000 doses by the end of the year and...produce 300,000 doses a month while the demand may even still exceed that," Yancopoulos said. "If the drug is really working and having the effects that we all hope it would, it could be doing a lot of good for a lot of people."
  • n
    neal
    The Chinese have stopped the spread of the virus but it will remain around until a vaccine is developed and can be administered to the general populations.

    I recommend people keep this reference, or knowledge, around in case you know someone who does reach the end stage of the viral expansion and high levels of IL-6 threaten to have them placed on a respirator. Try to convince the referring physician to consider it off label.
    Some patients infected with the novel coronavirus can develop uncontrolled immune response, leading to potentially life-threatening damage to lung tissue. After seeing promising results in clinical practice, Chinese authorities now recommend Roche's blockbuster arthritis drug Actemra to tackle that....

    FIERCEPHARMA.COM
    China turns Roche arthritis drug Actemra against COVID-19 in new treatment guidelines
    Some patients infected with the novel coronavirus can develop uncontrolled immune response, leading to potentially life-threatening damage to lung tissue. After seeing promising results in clinical practice, Chinese authorities now recommend Roche's blockbuster arthritis drug Actemra to tackle that....